natgillin/translations-raw huggingface dataset:
The pharmaceutical composition of claim 9 in the form of an oral dosage form. A process for manufacture of rasagiline tannate comprising: 
Farmaceutski sastav prema patentnom zahtjevu 9, naznačen time, da jest u obliku za oralno doziranje.
Alternative Method for Synthesizing 7,9-Acetal Linked Analogs 7,9 acetal linked analogs of 9,10-aa OH taxanes can also be formed directly from 10-deacetylbaccatin III (10-DAB), which has the formula: 
VII. Alternativni postanak za sintetiziranje 7,9-acetal vezanih analoga 7,9 acetalno vezani analozi 9,10-a,a OH taksana mogu također biti formirani direktno iz 10-deacetilbakatina III (10-
The method according to claim 4, wherein, when the wet adhesive composition is obtained from the composition of (e), the plasticizer is contained in amounts ranging from 10% to 35% by weight of the total weight of the wet adhesive composition. 
Uporaba u skladu s patentnim zahtjevom 2, pri čemu, kada su navedeni adhezivni sastavi tipa (e), oni sadrže količine plastifikatora u rasponu od 10-35% prema težini u odnosu na ukupnu težinu mokrih sastava.
freeze-drying the above solution. 
(b) sušenja smrzavanjem gore navedene otopine.
As shown in Figure 3, a locking groove 304 may be provided adjacent to the switch 302 . 
Kako je prikazano na Slici 3, utor 304 može biti priložen uz sklopku 302.
No. 4,100,046 the cycloalkenyl group is added to an fatty acid to obtain a heat-curable binder. 
U US 4,100,046 masnoj kiselini je dodana cikloalkenilna skupina, čime je dobiveno vezivo koje se može otvrdnuti pomoću topline.
The compound of claim 1, wherein R2 is selected from the group consisting of the following moieties: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R3 se bira iz skupine koju čine:
A compound for use according to claim 11 wherein the cancer is selected from a group consisting of: ovarian cancer, pancreatic cancer, breast cancer, prostate cancer and leukemia. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što se rak bira iz skupine koju čine: Tak jajnika, rak gušterače, rak dojke, rak prostate i leukemija.
In an alternative embodiemt the invention provides a bispecific single chain antibody comprising a first domain binding domain capable of binding to CD3 epsilon (CD3e) of human and non-chimpanzee primate and a second domain binding domain capable of binding to the extracellular domain of the mutated human FAPa chimera having an amino acid sequence as depicted in SEQ ID NO: 448 but not to the extracellular domain of the rodent FAPa. 
(b) vežuća domena, koja se može vezati na izvanstaničnu domenu kimere mutiranog ljudskog FAPa s aminokiselinskim slijedom kao što je opisan u SEQ ID NO: 448, gdje su aminokiselinski ostaci na položajima 144, 185, 186, 229, 267, 273, 274, 278, 284, 301, 328, 329, 331, 335 1 362 mutirani u odgovarajuće aminokiselinske ostatke FAPa divljeg tipa glodavca, no ne i na izvanstaničnu domenu FAPa divljeg tipa;
Crystal Violet present in amounts sufficient to result in concentrations at about 6 µM to about 10 µM under staining conditions; 
Kristal violet prisutno u dovoljnoj količini da se dobiju koncentracije od oko 6 uM do oko 10 uM u uvjetima bojenja;
The system of claim 16 wherein the fluid container size is in the range of a fraction of a liter to several liters in volume. 
Sustav prema zahtjevu 16, naznačen time što je veličina posude za fluid u opsegu od dijela jedne litre do nekoliko litara volumena.
The method according to claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at 4.99 and 23.23 degrees 2Θ (±0.1 degrees 2Θ), wherein said X-ray powder diffraction pattern is made using CuKa1 radiation. 
Postupak prema zahtjevu 1, naznačen time, da uzorak difrakcije praha X-zraka nadalje obuhvaća vršne vrijednosti na 4,99 i 23,23 stupnja 2θ (± 0,1 stupanj 2θ), pri čemu se navedeni uzorak difrakcije praha X-zraka dobiva uporabom CuKa1-radijacije.
The present invention pertains to compounds having the formula (I), 
HR P20100670 T1 PATENTNI ZAHTJEVI 5 1 Spoj formule (1),
The invention provides an oral transmucosal composition comprising therapeutically effective amount of insulin, an effervescent excipient component; and a bile salt for use in methods of treating diabetes in a recipient. 
PATENTNI ZAHTJEVI L ll. Oralni transmukozni pripravak naznačen time da sadrži: a) terapeutski učinkovitu količinu biološki aktivnog polipeptida; b) komponentu šumeće pomoćne tvari; i
For example, the amino acid may include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenyalanine, proline, serine, threonine, tryptophan, tyrosine, or valine. 
Tekućina za obradu prema zahtjevu 4, naznačena time što je aminokiselina alanin, arginin, asparagin, asparaginska kiselina, cistein, glutamin, glutaminska kiselina, glicin, histidin, izoleucin, leucin, lizin, metionin, fenilalanin, prolin, serin, treonin, triptofan, tirozin ili valin.
The method of claim 9, wherein the compound is administered orally. The method of claim 9, wherein the disorder is amyotrophic lateral sclerosis. 
Spoj za uporabu ili sastav za uporabu prema zahtjevu 8 ili 9, pri čemu poremećaj je amiotrofična lateralna skleroza.
A compound of claim 3 which is 2-[[2-(3-butoxy-phenyl)-ethyl]-(tetrahydrofuran-3-ylmethyl)amino]- N, N -dimethyl-acetamide and its pharmaceutically acceptable salts. 
Spoj u skladu s patentnim zahtjevom 3, naznačen time što je 2-[[2-(3-butoksifenil)etil](tetrahidrofuran-3-ilmetil)amino]-N,N-dimetilacetamid i njegove farmaceutski prihvatljive soli.
Apparatus according to any of the previous claims, characterized in that each of said ramps (11-1, 12-1, 13-1...) does show on the relevant upper edge (11-2, 12-2, 13-2...) a respective prolonged cavity (11-3, 12-3, 13-3...) able of lodging the lower edge of the respective rotating blade (11, 12, 13...). 
HR P20161661 T1 5. Uređaj prema bilo kojem od prethodnih zahtjeva, naznačen time da svaka od navedenih rampi (11-1, 12-1, 13-1...) ima na odgovarajućem gornjem rubu (11-2, 12-2, 13-2...) odgovarajuću produljenu šupljinu (11-3, 12-3, 13-3...) u koju se može smjestiti donji rub odgovarajuće rotirajuće oštrice (11, 12, 13..).
A method as claimed in any of Claims 1-3 wherein the selected ligand is from the agonist class of ligands and the particular conformation is an agonist conformation, or the selected ligand is from the antagonist class of ligands and the particular conformation is an antagonist conformation. 
Metoda iz Zahtjeva 1-3 naznačena time da je odabrani ligand iz skupine agonista, a određena konformacija je konformacija agonista ili je odabrani ligand iz skupine antagonista i određena konformacija je konformacija antagonista.
A combination according to para 22 for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with a microbial infection. 
4. - Kombinacija prema zahtjevu 1 ili zahtjevu 2 naznačena time da je za upotrebu za ubijanje ne-multiplicirajućih mikroorganizama povezanih s mikrobnom infekcijom.
The humanized CD37-specific binding protein according to any one of the preceding claims, wherein the light chain CDR1, CDR2 and CDR3 consist of the amino acid sequences of SEQ ID NOS:61, 64 and 66, respectively; and wherein the heavy chain CDR1, CDR2 and CDR3 consist of the amino acid sequences of SEQ ID NOS:63, 65, and 67, respectively; SEQ ID NOS:63, 65, and 68, respectively; SEQ ID NOS:63, 65, and 213, respectively; or SEQ ID NOS:63, 65, and 219, respectively. 
Humanizirani protein koji se specifično veže na CD37, ili protein koji se specifično veže na CD20, ili proizvodni artikl za upotrebu u liječenju karcinoma B-stanica ili autoimune bolesti navedeni u patentnim zahtjevima 1, 2 ili 3, pri čemu se laki lanci CDR1, CDR2 i CDR3 humaniziranog proteina koji se specifično veže na CD37 sastoje od aminokiselinskih slijedova iz SEQ ID NOS: 61, 64 i 66, slijedom kojim su navedeni; i pri čemu se teški lanci CDR1, CDR2 i CDR3 sastoje od aminokiselinskih slijedova iz SEQ ID NOS: 63, 65 i 67, slijedom kojim su navedeni.
The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein (a) A1 is C; or (b) A1 is N. 
Farmaceutski sastav prema zahtjevu 1, pri čemu je spoj spoj Formule II: [image] ili njegova farmaceutski prihvatljiva sol.
One embodiment of the present invention pertains to compounds of Formula (I) wherein Ring A is a 5-membered heterocyclic ring. In some embodiments, --- is a double bond and R2 is absent In some embodiments, Ring A is a 5-membered heterocyclic ring. 
Jedan oblik prikazanog izuma se odnosi na spojeve Formule (I) gdje Prsten A je 5-člani heterociklički prsten. U nekim oblicima, je dvostruka veza i R, odsutan. U nekim oblicima, Prsten A je 5-člani heterociklički rsten.
A compound according to the invention is given by Formula (I) 
Spoj prema izumu koji je prikazan s Formulom (1) ono) aka
The radioimmunoconjugate for use according to claim 9, wherein the therapy is selected from pretreatment, chemotherapy, monoclonal antibody therapy, surgery, radiotherapy, and/or photodynamic therapy. 
Radioimunokonjugat za primjenu u skladu sa zahtjevom 9, naznačen time što je terapija izabrana iz grupe koju čine prijetretman, kemoterapija, terapija monoklonskim antitijelima, kirurška intervencija, radioterapija i/ili fotodinamska terapija.
(e'-1) spray-freezing the aripiprazole suspension having a mean particle size within the range of about 1 to about 10 microns to obtain spray-frozen particles; and (e'-2) drying the spray-frozen particles to obtain spray-freeze-dried particles. 
(€-1) zamrzavanje raspršivanjem suspenzije aripiprazola koja ima srednju veličinu čestica od oko 1 do oko 10 mikrona da se dobiju čestice zamrznute raspršivanjem; i (€'-2) sušenje čestica zamrznutih raspršivanjem da se dobiju raspršivanjem zamrznute osušene čestice.
The present invention discloses compounds according to Formula I: 
Spoj, naznačen time, da je u skladu s Formulom I:
The solution according to claim 8, having the following composition Sodium mmol / l 134 
Otopina u skladu s patentnim zahtjevom 8, naznačena time što ima sljedeći sastav: natrij nnmol/l
The method of claim 9, further comprising disposing a sample into the lumen of the tube, and centrifuging the sample collection tube with the sample, the gel separator component layer material, and the photocurable sealant component layer material. 
Metoda prema zahtjevu 7, koja nadalje obuhvaća nanošenje uzorka u lumen epruvete, te centrifugu epruvete za uzimanje uzoraka krvi, sloja gel materijala separatora, i sloja materijala za brtvljenje putem svjetlosti.
The method of claim 14 comprising administering a pharmaceutical composition according to any of claims 1-13. The method of claim 14 or 15 further comprising administering an effective amount of one or more additional active agents selected from B2-agonists, PDE IV inhibitors, and corticosteroids. 
Aklidinij u slobodnom obliku ili u obliku farmaceutski prihvatljive soli za primjenu prema zahtjevu 11 ili 12, pri čemu se spomenuta primjena dalje sastoji od davanja djelotvorne količine jedne ili više dodatnih aktivnih tvari odabranih iz B2 agonista, inhibitora PDE IV 1 kortikosteroida.
Use of a compound of the formula [I] of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient for the production of a pharmaceutical agents for treating a disease causing by an undesirable cell proliferation. Use of claim 18, wherein the disease causing by an undesirable cell proliferation is rheumatism. 
Upotreba spoja formule [I] u skladu s patentnim zahtjevom 24, ili njegove farmaceutski prihvatljive soli, naznačena time što je spoj formule [I] aktivni sastojak u proizvodnji farmaceutskog sredstva za liječenje bolesti koju uzrokuje nepoželjna stanična proliferacija.
The length of the article was about 77 mm. 
Dužina proizvoda bila je oko 77 mm.
Also disclosed are compounds of Formula (I) wherein: 
PATENTNI ZAHTJEVI 1. Spoj formule (I)
A T-cell preparation as defined in any one of claims 1-5, a T-cell mixture as defined in any one of claims 6-14, or a pharmaceutical composition as defined in claim 15, for use in the prophylaxis and/or treatment of cancer. 
Peptidna smjesa u skladu sa bilo kojim od patentnih zahtjeva 1-3, smjesa T stanica u skladu sa patentnim zahtjevom 4 ili farmaceutska kompozicija u skladu sa patentnim zahtjevom 5 za primjenu u profilaksi i/ili liječenju raka kod pacijenta.
an antisense strand that comprises the sequence of SEQ ID NO: 1296; 
dsRNA prema zahtjevu 1, 2 ili 3, naznačena time da antisensni lanac sadrži sekvencu iz SEQ ID NO: 1296.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
The amorphous zirconia ZrOx(OH)4-2x was precipitated with 1.5 M NH3 at a constant pH of 10. 
Amorfna cirkonija (ZrO(OH)42,) je taložena s 1.5 M NH; pri konstantnom pH od 10.
The methyl 2-(2-chlorobenzylidine) acetoacetate (115 g) was added and heating under reflux continued for 4 hours. 
Doda se metil 2-(2-klorobenzilidin)acetoacetat (115 g) i zagrijavanje pod refluksom se nastavi 4 sata.
The formulation of item 2, wherein said formulation is in the form of a tablet, wherein said tablet is not a monolithic tablet or a trilayer tablet, said trilayer tablet having an inert excipient layer as the middle layer. 
Formulacija patentnog zahtjeva 2, pri čemu navedena tableta nije troslojna tableta, navedena troslojna tableta koja ima inertni sloj ekscipijensa kao srednji sloj. Formulacija patentnog zahtjeva 3, pri čemu navedena dvoslojna tableta ne pokazuje vidljive pukotine.
• and internally, on its bottom part, an anti-drip ball (34) made of silicone. 
unutra, na svom donjem dijelu, kuglicu protiv kapanja (34), načinjenu od silikona.
wherein the process is a compression- and compaction-free process. The pharmaceutical blend according to claim 7 wherein said drug substance is present as phosphate salt, preferably as mono-phosphate, more preferably as anhydrous mono-phosphate, even more preferably as anhydrous mono-phosphate salt in a polymorphic form characterized by an XRPD peak (2theta) at 15.0° ± 0.2°. 
Farmaceutska mješavina prema patentnom zahtjevu 7, gde je navedena supstanca lijeka je prisutna kao fosfatna sol, poželjno kao mono-fosfat, poželjnije kao anhidrirani mono-fosfat, čak poželjnije kao anhidrirana monofosfatna sol u polimorfnom obliku naznačena XRPD pikom (2teta) na 15.0% #£ 0.2".
The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein, having Formula IIa: or a pharmaceutically acceptable salt thereof. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein, having Formula IIIa: 
HR P20170795 T1 ili njegova farmaceutski prihvatljiva sol; ili d) ima formulu IIa: Ha ili njegova farmaceutski prihvatljiva sol; ili e) ima formulu IIIa: ili njegova farmaceutski prihvatljiva sol; ili f) ima formulu IVa:
Nifuratel for use according to claim 8, characterized in that said at least one antibiotic is selected from: clindamycin, macrolide antibiotics such as erythromycin, oleandomycin, flurithromycin, azithromycin and claritromycin and salts thereof, beta-lactam antibiotics such as penicillin, ampicillin, amoxicillin and salts thereof, fluoroquinolones such as ofloxacine, norfloxacine, ciprofloxacine and salts thereof, aminoglycosides such as gentamycin, amikacin, kanamycin, neomycin and salts thereof. 
Nifuratel, namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što se navedeni najmanje jedan antibiotik bira između: klindamicina, makrolidnih antibiotika, poput eritromicina, oleandomicina, fluritromicina, azitromicina i klaritromicina i njihovih soli, f-laktamskih antibiotika, poput penicilina, ampicilina, amoksicilina i njihovih soli, fluorkinolona, poput ofloksacina, norfloksacina, ciprofloksacina i njihovih soli, aminoglikozida, poput gentamicina, amikacina, kanamicina, neomicina i njihovih soli.
The antibody of embodiment 7 wherein, said antibody comprises an amino acid substitution of L235E of the Fc region. 
Protutijelo prema zahtjevu 1 ili zahtjevu 2, naznačeno time da protutijelo nadalje sadrži supstituciju amino kiseline od L235E i / ili P331 S.
Y represents a carbonyl group or a methylene group optionally substituted by a hydroxyl group; and p represents 2 and q represents 0. 
Y predstavlja karbonilnu skupinu ili metilensku skupinu, izborno supstituiranu s hidroksilnom skupinom; i p Znači 2, a q znači 0.
A kit of parts comprising (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 together with instructions for simultaneous, concurrent, separate or sequential use in combination with (a) a long-acting B2 agonist as defined in any one of claims 1 and 3 to 6 for the treatment of a patient suffering from or susceptible to a respiratory disease as defined in claim 9. 
Komplet dijelova koji sadrži (b) antagonist M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 ili 2 zajedno s uputama za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u kombinaciji s B2 agonistom kako je definirano u zahtjevu 1 ili 3, naznačen time, da je namijenjen za uporabu pri liječenju pacijenata koji pate od ili su podložni bolestima dišnih putova kako je definirano u zahtjevu 7 ili 8.
(R1R2N)C1-C6 alkyl-, wherein said alkyl portion is optionally substituted with OH and wherein R1 and R2 are independently H or C1-C6 alkyl (optionally substituted with 1-3 fluoros); 
(R1R2N)C1-C6 alkil-, gdje navedeni alkilni dio može biti supstituiran s OH, te gdje su R1 i R2 neovisno H ili C1-C6 alkil (koji može biti supstituiran s 1-3 fluora);
A modified serpin according to clause 14 wherein the P2 residue is mutated to K. 
Modificirani serpin prema zahtjevu 1 ili zahtjevu 2, naznačen time, da ostatak P2 je mutiran na K.
A developer supply container according to Claim 19, wherein said nozzle portion is provided with a plurality of such openings around a free end side thereof. 
Spremnik za nadopunjavanje razvijača u skladu s patentnim zahtjevom 19, naznačen time što navedena mlaznica (47) ima više otvora (51) oko svoje strane sa slobodnim krajem.
An object according to claim 9, wherein the at least one layer has a flexibility ranging from 1 to 9 mm measured according to ISO1520:1999. 
Objekt sukladno bilo kojem od prethodnih Zahtjeva, naznačen time što sloj ima fleksibilnost u opsegu od 1 do 9 mm mjereno sukladno 1S01520:1999.
A method according to claim I or claim 2 wherein said determining is through the use of a Melanophore assay, through the use of a reporter assay, or through the measurement of GTPYS binding to a membrane comprising said GPCR. 
Postupak u skladu sa zahtjevom 1 ili zahtjevom 2, naznačen time, da se navedeno određivanje provodi preko uporabe Melanophore ispitivanja, preko uporabe ispitivanja izvješća ili preko mjerenja vezivanja GTPyS na membranu koja sadrži navedeni GPCR.
An insulin conjugate prepared by linking insulin with an immunoglobulin Fc region via a polyethylene glycol in which the polyethylene glycol is linked to the amino terminal of beta chain of insulin. 
Konjugat inzulina pripremljen vezivanjem inzulina sa Fc regijaom imunoglobulina preko polietilen glikola u kome je polietilen glikol vezan za amino terminus beta lanca inzulina .
It may be formulated for any suitable route of administration, including but not limited to intravenous, intramuscular, intraperitoneal, nasal, subcutaneous, intradermal, etc. 
Sastav prema bilo kojem od zahtjeva 1 do 4, naznačen time, da se formulira za intravenoznu, intramuskularnu, intraperitonealnu, nazalnu, subkutanu ili intradermalnu primjenu.
The pharmaceutical composition according to claim 18, further comprising a pharmaceutically acceptable carrier. 
Farmaceutski sastav prema zahtjevu 21, koji nadalje sadrži farmaceutski prihvatljiv nosač.
Due to these intramolecular hydrogen bonds and to the hydrogen bridges formed via interactions between HA and the water being present in the biological systems, HA has a complicated three dimensional structure (C. L. Hew et al., Eur. 
Sukladno tim unutarmolekularnim vodikovim vezama i formiranim vodikovim mostovima pomoću interakcija između HA i vode, koja je prisutna u biološkim sistemima, HA ima kompliciranu trodimenzionalnu strukturu. (C. L. Hew et al., Eur.
The wet granulated pharmaceutical composition according to claim 5 or 6, wherein said composition also contains at least one active drug in addition to Candesartan cilexetil. 
Vlažno granulirani farmaceutski pripravak u skladu s patentnim zahtjevom 5 ili 6, naznačen time što navedeni pripravak također sadrži najmanje jedan aktivni lijek uz kandesartan-cileksetil.
The drug substance of Claim 12 comprising about 75% to about 100% by weight of said crystalline monohydrate. 
Supstanca lijeka iz Zahtjeva 12, naznačena time, da sadržava oko 75% do oko 100% težinski spomenutog kristalnog monohidrata.
a pusher limit switch, controlled by the passage detector and suitable for adopting: 
39), koju kontrolira detektor prolaza i koja može zauzeti:
In some embodiments of the present invention, the composition and/or the granules within the composition can comprise microcrystalline cellulose and starch in a weight ratio ranging from about 1:1 to about 15:1. 
Smjesa prema zahtjevu 1, gdje smjesa sadrži mikrokristaliničnu celulozu i škrob u težinskom omjeru u rasponu od 1:1 do 15:1, poželjno u težinskom omjeru od 10:1.
A jar according to claim 1 wherein the external portion of the adjuster mandrel includes a collar that is moveable relative to the remainder of the adjuster mandrel and has a protuberance that is engageable with a shoulder defined in the hollow housing; and wherein the adjuster mandrel includes a threaded portion having threadedly engaged therewith a lock nut that on tightening engages the collar to force the protuberance into engagement with the shoulder and thereby prevent operation of the adjuster. 
Udarac (10), prema Zahtjevu 1, naznačen time, što vanjski dio vretena (47) podešivača sadrži ogrlicu koju je moguće pomicati u odnosu na ostatak vretena podešivača i ima ispupčenja (54) koja su zahvaćena ramenom (56) koji je u šupljem kućištu i što vreteno podešivača sadrži dio s navojem koji je navojem u vezi s navrtkom za zabravljivanje, koji pritezanjem zahvaća ogrlicu da potisne ispupčenja u sklop s ramenom i time spriječi rad podešivača,
The variant of claim 10, comprising the substitutions P10Q+K32E+A34L+R36E. 
Varijanta iz zahtjeva 10, naznačena time, da sadrži supstitucije PIOQ+K32F+A34L+R36E.
The device according to the preceding claims, characterized in that said tube (11) has a cross-section that comprises three lobes (13, 14, 15) arranged substantially at 120 sexagesimal degrees with respect to each other. 
Uređaj u skladu s prethodnim patentnim zahtjevima, naznačen time, da svaki od navedenih dijelova cijevi (11a, 11b, llc, 11d) ima poprečni presjek koji se sastoji od tri režnja (13,14,15) međusobno raspoređena uglavnom na 120 šezdesetih stupnjeva.
represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted by a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom; 
predstavlja 2-, 3- ili 4-piridinski prsten ili 2-, 4- ili 5-pirimidinski prsten, gdje je navedeni prsten izborno supstituiran s C1-6 alkilnom skupinom, C1-6 alkoksi skupinom ili atomom halogena;
Hooking to a Mooring Buoy The user laces the control levers in their neutral positions, and activates the system as described above. 
5. Privezivanje uz sidrenu plutaču Korisnik postavlja upravljačke kontrole u njihov neutralni položaj te aktivira sustav kao što je gore opisano.